Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
SSE:688505.SS
8.58 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 701.966 | 845.343 | 1,031.16 | 1,140.313 | 833.803 | 1,029.295 | 740.422 | 497.694 | 621.87 | 579.463 | 470.9 | 415.925 | 232.527 | 133.89 | 92.39 | 61.905 | 31.99 | 24.927 | 19.764 | 20.117 |
| Cost of Revenue
| 108.412 | 74.076 | 84.062 | 80.955 | 62.839 | 73.341 | 76.297 | 54.791 | 46.512 | 50.014 | 36.821 | 32.407 | 23.557 | 23.034 | 18.7 | 16.185 | 12.209 | 10.88 | 9.413 | 12.093 |
| Gross Profit
| 593.554 | 771.267 | 947.098 | 1,059.358 | 770.964 | 955.954 | 664.125 | 442.903 | 575.358 | 529.449 | 434.079 | 383.518 | 208.97 | 110.856 | 73.69 | 45.72 | 19.781 | 14.047 | 10.351 | 8.024 |
| Gross Profit Ratio
| 0.846 | 0.912 | 0.918 | 0.929 | 0.925 | 0.929 | 0.897 | 0.89 | 0.925 | 0.914 | 0.922 | 0.922 | 0.899 | 0.828 | 0.798 | 0.739 | 0.618 | 0.564 | 0.524 | 0.399 |
| Reseach & Development Expenses
| 285.239 | 248.716 | 226.851 | 224.387 | 139.268 | 127.822 | 114.284 | 110.426 | 95.046 | 110.116 | 105.071 | 68.108 | 45.312 | 32.891 | 23.819 | 22.108 | 16.004 | 15.863 | 15.57 | 24.438 |
| General & Administrative Expenses
| 0 | 16.059 | 12.948 | 16.411 | 17.429 | 13.391 | 93.579 | 54.509 | 36.485 | 28.876 | 22.65 | 20.772 | 16.81 | 17.371 | 11.124 | 11.848 | 12.156 | 11.309 | 10.726 | 12.417 |
| Selling & Marketing Expenses
| 0 | 383.187 | 554.631 | 599.697 | 426.929 | 530.571 | 350.469 | 253.003 | 349.838 | 309.038 | 258.025 | 232.057 | 126.62 | 54.596 | 52.646 | 30.483 | 21.701 | 18.987 | 0 | 0 |
| SG&A
| 313.797 | 450.351 | 567.579 | 616.108 | 444.358 | 543.963 | 444.048 | 307.512 | 386.323 | 337.914 | 280.675 | 252.829 | 143.43 | 71.967 | 63.77 | 42.331 | 33.857 | 30.296 | 10.726 | 12.417 |
| Other Expenses
| -2.245 | -19.5 | 29.124 | 30.413 | 22.985 | 33.528 | 1.605 | 0.965 | 1.031 | 2.871 | 0.931 | 0.075 | 0.024 | -34.608 | -20.831 | -13.669 | -7.847 | -0.943 | -0.448 | -2.9 |
| Operating Expenses
| 601.281 | 679.568 | 823.553 | 870.908 | 606.612 | 705.313 | 530.871 | 382.93 | 431.871 | 391.89 | 312.687 | 279.352 | 146.924 | 70.25 | 66.758 | 50.77 | 42.014 | 41.991 | 31.66 | 39.781 |
| Operating Income
| -7.727 | 97.09 | 133.271 | 217.378 | 173.031 | 247.482 | 150.264 | 76.001 | 155.117 | 153.056 | 129.96 | 108.36 | 63.866 | 42.489 | 6.932 | -5.05 | -21.647 | -26.752 | -21.309 | -31.757 |
| Operating Income Ratio
| -0.011 | 0.115 | 0.129 | 0.191 | 0.208 | 0.24 | 0.203 | 0.153 | 0.249 | 0.264 | 0.276 | 0.261 | 0.275 | 0.317 | 0.075 | -0.082 | -0.677 | -1.073 | -1.078 | -1.579 |
| Total Other Income Expenses Net
| 41.738 | 0.438 | -0.978 | -1.457 | 3.67 | -1.17 | -56.374 | -5.505 | -4.279 | -7.106 | -1.861 | -9.414 | -8.852 | -4.862 | -2.946 | -2.545 | -1.483 | -2.195 | -0.448 | -2.9 |
| Income Before Tax
| 34.011 | 97.528 | 132.294 | 215.921 | 176.701 | 246.312 | 143.07 | 70.496 | 150.838 | 145.95 | 128.099 | 98.946 | 57.7 | 37.627 | 3.986 | -7.595 | -23.13 | -28.947 | -21.757 | -34.657 |
| Income Before Tax Ratio
| 0.048 | 0.115 | 0.128 | 0.189 | 0.212 | 0.239 | 0.193 | 0.142 | 0.243 | 0.252 | 0.272 | 0.238 | 0.248 | 0.281 | 0.043 | -0.123 | -0.723 | -1.161 | -1.101 | -1.723 |
| Income Tax Expense
| -33.976 | -10.922 | -4.979 | 3.54 | 12.442 | 25.657 | 13.304 | 10.337 | 20.83 | 18.903 | 17.605 | 15.405 | 5.264 | 5.255 | 2.801 | 0.879 | 1.069 | 1.709 | 0.273 | -4.301 |
| Net Income
| 39.734 | 108.627 | 137.997 | 213.296 | 164.663 | 227.358 | 150.982 | 75.287 | 138.708 | 127.723 | 118.258 | 87.218 | 53.159 | 30.826 | 3.681 | -7.32 | -23.402 | -29.55 | -22.03 | -30.356 |
| Net Income Ratio
| 0.057 | 0.129 | 0.134 | 0.187 | 0.197 | 0.221 | 0.204 | 0.151 | 0.223 | 0.22 | 0.251 | 0.21 | 0.229 | 0.23 | 0.04 | -0.118 | -0.732 | -1.185 | -1.115 | -1.509 |
| EPS
| 0.038 | 0.11 | 0.13 | 0.2 | 0.17 | 0.25 | 0.16 | 0.082 | 0.15 | 0.14 | 0.13 | 0.1 | 0.075 | 0.043 | 0.005 | -0.01 | -0.033 | -0.042 | -0.031 | -0.043 |
| EPS Diluted
| 0.038 | 0.11 | 0.13 | 0.2 | 0.17 | 0.25 | 0.16 | 0.082 | 0.15 | 0.14 | 0.13 | 0.1 | 0.075 | 0.043 | 0.005 | -0.01 | -0.033 | -0.042 | -0.031 | -0.043 |
| EBITDA
| 80.252 | 160.522 | 236.562 | 280.519 | 240.122 | 319.488 | 157.393 | 123.347 | 184.961 | 181.303 | 155.757 | 120.238 | 74.874 | 49.313 | 14.656 | 2.192 | -15.476 | -20.83 | -14.911 | -31.757 |
| EBITDA Ratio
| 0.114 | 0.19 | 0.229 | 0.246 | 0.288 | 0.31 | 0.213 | 0.248 | 0.297 | 0.313 | 0.331 | 0.289 | 0.322 | 0.368 | 0.159 | 0.035 | -0.484 | -0.836 | -0.754 | -1.579 |